Arctic Bioscience - Report Publication Announcement 2024

Arctic Bioscience - Invitation to presentation of Q4 2023 operational update

Arctic Bioscience will publish a Q4 2023 operational update and preliminary full

year 2023 financial results on Friday 1[st] of March, at 08:00 CET.

The same day at 11:00 CET, the Company will host a webcast to present the

results and give an operational update. Following the presentation, it will be

opened for questions from the audience.

Webcast details:

Date: Friday 1[st] of March 2024

Time: 11:00 CET

Format: Webcast and Q&A

Language: English

The presentation can be accessed through the Company's website, or with the link

below:

Link: https://channel.royalcast.com/landingpage/hegnarmedia/20240301_1/

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.

For more information, please contact:

Christer L. Valderhaug

CEO

Phone: +47 920 84 601

Jone R. Slinning

CFO

Mobile: +47 948 75 469

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing

pharmaceutical and nutraceutical products based on unique bioactive marine

compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being

developed for treatment of patients with mild-to-moderate psoriasis. This is a

large patient group in need of new effective medicines with beneficial safety

profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as

well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and

highly relevant background.

AI assistant